Literature DB >> 19471652

Clinical significance of postoperative CA-125 level after primary cytoreductive surgery in ovarian cancer.

Hee Seung Kim1, Noh Hyun Park.   

Abstract

Entities:  

Year:  2008        PMID： 19471652      PMCID： PMC2676482          DOI： 10.3802/jgo.2008.19.4.279

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN： 2005-0380            Impact factor:   4.401


× No keyword cloud information.
  6 in total

1.  Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

Authors:  S M Crawford; J Peace
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

2.  Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Authors:  F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Authors:  Margrit M Juretzka; Richard R Barakat; Dennis S Chi; Alexia Iasonos; Jakob Dupont; Nadeem R Abu-Rustum; Elizabeth A Poynor; Carol Aghajanian; David Spriggs; Martee L Hensley; Paul Sabbatini
Journal:  Gynecol Oncol       Date:  2006-09-25       Impact factor: 5.482

4.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

5.  Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.

Authors:  Hee Seung Kim; Noh-Hyun Park; Hyun Hoon Chung; Jae Weon Kim; Yong-Sang Song; Soon-Beom Kang
Journal:  Onkologie       Date:  2008-05-27

6.  Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.

Authors:  Gamal H Eltabbakh; Sharon L Mount; Barbara Beatty; Linda Simmons-Arnold; Kumarasen Cooper
Journal:  J Surg Oncol       Date:  2006-04-01       Impact factor: 3.454
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.